Iovance Biotherapeutics Inc
IOVA2.286USD
-0.084-3.53%
Horário de mercado （ET）Cotações atrasadas em 15 min
781.73MValor de mercado
PerdaP/L TTM
Mais detalhes de Iovance Biotherapeutics Inc Empresa
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Informações da empresa
Código da empresaIOVA
Nome da EmpresaIovance Biotherapeutics Inc
Data de listagemJun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Número de funcionários838
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 20
Endereço825 Industrial Road
CidadeSAN CARLOS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94070
Telefone16502607120
Sitehttps://www.iovance.com/
Código da empresaIOVA
Data de listagemJun 20, 2008
CEODr. Frederick G. Vogt, J.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Dr. Friedrich Graf Finckenstein, M.D.
Dr. Friedrich Graf Finckenstein, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
434.56K
+7.40%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
212.86K
+1.43%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
99.69K
+6.47%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
48.52M
98.37%
Rest of world
804.00K
1.63%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
Outro
68.67%
Investidores
Investidores
Proporção
MHR Fund Management LLC
8.01%
Quogue Capital L.L.C.
7.76%
The Vanguard Group, Inc.
6.92%
BlackRock Institutional Trust Company, N.A.
5.39%
Long Focus Capital Management LLC
3.27%
Outro
68.67%
Tipos de investidores
Investidores
Proporção
Investment Advisor
21.45%
Hedge Fund
16.62%
Investment Advisor/Hedge Fund
9.65%
Private Equity
8.01%
Venture Capital
7.77%
Research Firm
5.49%
Individual Investor
0.36%
Bank and Trust
0.25%
Pension Fund
0.18%
Outro
30.24%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
654
271.34M
81.00%
-28.55M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
MHR Fund Management LLC
24.42M
7.31%
--
--
Mar 31, 2025
Quogue Capital L.L.C.
28.07M
8.4%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
27.73M
8.3%
+243.44K
+0.89%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
6.15%
+368.21K
+1.83%
Mar 31, 2025
Long Focus Capital Management LLC
9.25M
2.77%
+4.12M
+80.24%
Mar 31, 2025
State Street Global Advisors (US)
11.04M
3.31%
-1.21M
-9.86%
Mar 31, 2025
Invenomic Capital Management LP
5.49M
1.64%
+5.49M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
5.97M
1.79%
+96.88K
+1.65%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
Virtus LifeSci Biotech Products ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Russell 2000 ETF
0%
Ver Mais
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
iShares Biotechnology ETF
Proporção0%
SPDR S&P Kensho New Economies Composite ETF
Proporção0%
Virtus LifeSci Biotech Products ETF
Proporção0%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0%
iShares Genomics Immunology and Healthcare ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Fidelity MSCI Health Care Index ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
